OncoLink is committed to respecting your privacy. We've structured our Web site so that, in general, you can visit OncoLink on the Web without identifying yourself or revealing any personal information. Once you choose to provide us personally identifiable information (any information by which you can be identified), you can be assured that it will only be used to support your relationship with OncoLink.
On some OncoLink web pages, you can make requests, and register to receive materials. The types of personal information collected at these pages are name and contact information. In order to tailor our subsequent communications to you and continuously improve our products and services, we may also ask you to voluntarily provide us with information regarding your experience with cancer, personal or professional interests, demographics and contact preferences.
OncoLink uses your information to better understand your needs and provide you with better service. Specifically, we use your information to help you complete a transaction, to communicate back to you, to update you on service and benefits, and to personalize our web site for you.
From time to time, we may also use your information to contact you for market research or to provide you with marketing information we think would be of particular interest. At a minimum, we will always give you the opportunity to opt out of receiving such direct marketing or market research contact. We will also follow local requirements, such as allowing you to opt in before receiving unsolicited contact, where applicable.
OncoLink will not sell, rent, or lease your personally identifiable information to others. Unless we have your permission or are required by law, we will only share the personal data you provide online with other OncoLink entities and/or business partners who are acting on our behalf to complete the activities described above. Such OncoLink entities and/or business partners, including those located in other countries, are governed by our privacy policies with respect to the use of this data.
OncoLink will not use or share the personally identifiable information provided to us online in ways unrelated to the ones described above without letting you know and offering you a choice. As previously stated, we will also provide you the opportunity to let us know if you do not wish to receive unsolicited direct marketing materials from us and we will do everything we can to honor such requests.
OncoLink is committed to ensuring the security of your information. To prevent unauthorized access, maintain data accuracy, and ensure the appropriate use of information, we have put in place appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online. We use encryption when collecting or transferring sensitive data such as credit card information.
Jun 16, 2011 - The U.S. Food and Drug Administration has approved the Inform Dual ISH test, a genetic test to determine whether women with breast cancer are human epidermal growth factor receptor 2-positive and therefore candidates for trastuzumab (Herceptin).